Voyager Therapeutics Inc.
VYGR | NASDAQ
$3.11
+$0.03 (+0.97%)
Sep 22, 2026, 11:59 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -1.93 | -5.02 | 2.74 | -5.04 | -1.55 | 7.22 |
PEG Ratio | -0.02 | 0.04 | -0.01 | 0.16 | 0.01 | -0.04 |
PS Ratio | 5.71 | 4.09 | 1.45 | 5.72 | 2.73 | 1.55 |
PB Ratio | 1.18 | 1.09 | 1.54 | 3.96 | 1.07 | 1.72 |
P/FCF Ratio | -1.71 | -17.36 | 4.86 | -15.60 | -1.85 | -2.44 |
P/OCF Ratio | -1.74 | -21.36 | 4.66 | -18.70 | -1.91 | -2.75 |
OCF/S Ratio | -328.10 | -19.14 | 31.17 | -30.58 | -143.06 | -56.52 |
Debt / Equity Ratio | 0.19 | 0.15 | 0.09 | 0.39 | 0.46 | 0.31 |
Quick Ratio | 7.64 | 5.56 | 4.96 | 1.72 | 2.68 | 7.39 |
Current Ratio | 7.64 | 5.56 | 4.96 | 1.72 | 2.68 | 7.39 |
Asset Turnover | 0.16 | 0.20 | 0.71 | 0.26 | 0.19 | 0.65 |
Interest Coverage | n/a | n/a | n/a | n/a | n/a | n/a |
Return on Equity | -61.06% | -21.68% | 56% | -78.63% | -74.90% | 23.81% |
Return on Assets | -47.46% | -16.54% | 37.67% | -29.12% | -36.73% | 14.05% |
Return on Invested Capital | -56.44% | -23.76% | 41.63% | -56.74% | -49.59% | 11.46% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | -227.62% | 100% | 63.13% | -36.32% | -97.21% | 36.45% |
Net Profit Margin | -296.53% | -81.25% | 52.93% | -113.45% | -190.29% | 21.47% |
Pretax Profit Margin | -296.17% | -80.42% | 53.49% | -113.41% | -190.29% | 21.47% |
Operating Profit Margin | -326.56% | -104.11% | 48.80% | -124.27% | -196.76% | 16% |
FCF Margin | -334.53% | -23.54% | 29.86% | -36.67% | -147.36% | -63.59% |
EBITDA Margin | -286.12% | -74.51% | 55.27% | -96.92% | -176.49% | 18.23% |
Add to Watchlist
Select watchlists to add or remove VYGR